-

Shareholder Alert: Robbins LLP is Investigating EBIX, Inc. (EBIX) for Shareholders

SAN DIEGO & JOHNS CREEK, Ga.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating EBIX, Inc. (NASDAQ: EBIX) to determine whether certain Ebix officers and directors violated the Securities Exchange Act of 1934 and breaching their fiduciary duties to the Company. Ebix supplies infrastructure exchanges to the insurance, financial, travel, cash remittances, and healthcare industries.

If you suffered a loss due to Ebix, Inc.'s misconduct, click here.

Ebix, Inc. (EBIX) Misled Shareholders About the Adequacy of its Internal Controls of Financial Reporting

According to a complaint filed against the Company, on February 19, 2021, after the market closed, Ebix revealed that its independent auditor, RSM US LLP, resigned because it was unable "to obtain sufficient appropriate evidence that would allow it to evaluate the business purpose of significant unusual transactions that occurred in the fourth quarter of 2020" related to the Company's business gift card business in India. RSM also stated that the Company's "internal control over financial reporting was not effective as of December 31, 2020 due to the identification of material weaknesses" related to Ebix's failure to design controls "over the gift or prepaid card revenues transaction cycle sufficient to prevent or detect a material misstatement." Further, Ebix and RSM disagreed over the accounting treatment of $30 million that had been transferred into a commingled trust account of Ebix's outside counsel in December 2020. On this news, Ebix shares fell over $20, or approximately 40%, on February 22, 2021.

Ebix, Inc. (EBIX) shareholders have options. If you would like more information regarding your rights, please contact Lauren Levi at (800) 350-6003 or llevi@robbinsllp.com, or via our Shareholder Information Form.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Ebix, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800)...

Investor Notice: Robbins LLP Informs Investors of the Gemini Space Station, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gemini Space Station, Inc. (NASDAQ: GEMI) Class A common stock pursuant and/or traceable to the Company's September 12, 2025 initial public offering ("IPO"), and/or Gemini Space Station, Inc. securities between September 12, 2025 and February 17, 2026. Gemini was founded to develop and operate a cryptocurrency platform. For more information, s...

uniQure N.V. Stockholders Should Contact Robbins LLP for Information About Leading the QURE Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? September 24, 2025 – October 31, 2025 W...
Back to Newsroom